TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASEPRNewsWire • 09/24/24
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASEPRNewsWire • 09/23/24
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right NowThe Motley Fool • 09/12/24
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024PRNewsWire • 09/09/24
Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/05/24
Amgen Inc. (AMGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/04/24
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug RaceInvestors Business Daily • 08/29/24